$2.89
-0.02 (-0.69%)
Open$2.89
Previous Close$2.91
Day High$2.93
Day Low$2.78
52W High$26.76
52W Low$15.80
Volume—
Avg Volume386.2K
Market Cap232.42M
P/E Ratio15.34
EPS$1.58
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+979.9% upside
Current
$2.89
$2.89
Target
$31.21
$31.21
$17.92
$31.21 avg
$31.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 393.46M | 361.03M | 312.42M |
| Net Income | 16.94M | 15.50M | 9.93M |
| Profit Margin | 4.3% | 4.3% | 3.2% |
| EBITDA | 28.43M | 29.24M | 21.92M |
| Free Cash Flow | 9.51M | 6.36M | 8.25M |
| Rev Growth | -6.4% | +17.6% | +23.0% |
| Debt/Equity | 0.66 | 0.65 | 0.80 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |